Open Study of the Efficacy of the Local Treatment With Polygynax of

Status Completed

Clinical Trial Summary

Open prospective multicenter phase IV study in patients presenting with symptoms of bacterial and/or mycotic (mushroom) vaginitis for 12 days as specified in the product information.

Investigators/centers: 20 gynacologists are previewed to do the study in ambulatory treatment.

Objectifs of the study:

Principal objectif:

Evaluation of the efficacy of the treatment on the clinical symptoms of bacterial and/or mycotic vaginitis

Secondary objectif:

Evaluation of the efficacy of the treatment on eradication of the diagnosed germs Evaluation of the correspondence of the efficacy on the symptoms and on the eradication of the germs.

Numbers of patients previewed: 100 patients for evaluation of the efficacy

Criteria of evaluation

Principal criteria:

Clinical efficacy as judged by the investigator Secondary criteria:evaluation of clinical symptoms judged by the patient reduction or emlimination of bacteria and other germs the relationship between clinical and bacterial results

Evaluation of tolerance

Used Study Drug:

Polygynax, vaginal capsule consisting of Polymyxin 35000 UI, Neomycin 35000UI and Nystatin 100000UI Application: vaginal application once daily in the evening for 12 days

Study design:

Visit 1:

All patients presenting with the clinical symptoms, presenting all inclusion criteria and none of the exclusion criteria are included in the study at visit 1 and receive Polygynax treatment (one vaginal capsule once daily in the evening).

A vaginal smear is obtained. Visit 2 (optional) If the results of the bacteriological examination confirms an infection with germs sensible to the treatment with Polygynax the treatment is continued. If other germs not sensible to Polygynax are present, the patients is contacted to stop the treatment, to come back to a second visit to her gynacologist who will change the treatment. The other patients continue the treatment.

Visit 3:

After the treatment the patients come back to the last visit. A clinical evaluation and a vaginal smear for control is obtained.

Clinical Trial Description

n/a

Study Design

Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

Vaginitis

Clinical Trial Details

NCT number	NCT02444481
Study type	Interventional
Source	Laboratoire Innotech International
Contact
Status	Completed
Phase	Phase 4
Start date	April 2009
Completion date	November 2009

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT02515656` - Assessment of the Efficacy of POLYGYNAX® in the Empirical Treatment of Infectious Vaginitis	Phase 3
Recruiting	`NCT01420510` - Saginil in vs. Placebo for Gynecologic Oncology Patients Affected by Vaginitis	Phase 2/Phase 3
Completed	`NCT04079218` - Accelerated Genital Tract Aging in HIV: Estradiol Clinical Trial	Phase 4
Recruiting	`NCT05557318` - Using Micro Electro Mechanical Systems to Detect the Air of Vaginal Discharge	N/A
Completed	`NCT01436513` - A Study To Compare The Amount Of Premarin Components That Is Absorbed Into The Blood Of Japanese Healthy Postmenopausal Women Following Oral Administration Of Two Different Tablets Of Premarin Under Fast and Fed Conditions.	Phase 1
Completed	`NCT03585049` - Microscopic Images for the Development of a Rapid Vaginitis Diagnostic Device
Completed	`NCT04676503` - Vaginal and Rectal Colonization of Lactobacillus Crispatus NTCVAG04 Following Oral Administration in Patients With History of Vaginitis/Vaginosis	N/A
Completed	`NCT02641717` - Validity of Patient-Collected Wet Mounts	N/A
Recruiting	`NCT05587283` - Safety, Tolerability, and Acceptability Study of Intravaginal Administration of LABTHERA-001 Capsules in Healthy Women	Phase 1
Not yet recruiting	`NCT06070454` - Prospective Evaluation of Infectious Vulvovaginitis on Wound Complication Rates After Vulvar Excision for Premalignant Lesions	N/A
Completed	`NCT02365389` - Once Daily In-situ Forming Versus Twice-daily Conventional Metronidazole Vaginal Gels for Treatment of Bacterial Vaginosis	Phase 2/Phase 3
Completed	`NCT01050465` - MedlinePlus Health Prescriptions: Developing a Pragmatic Approach for Clinic Use	N/A
Completed	`NCT05652959` - Real-world Performance and Safety of Cerviron® in the Treatment of Vaginitis
Recruiting	`NCT02763696` - Establishment of a Sensitive System for Analysis of Child-bearing Women Vaginal Microbiota	N/A
Recruiting	`NCT04574089` - Treatment for Aerobic Vaginitis by Using Bofukang Vaginal Suppository	Phase 3
Recruiting	`NCT04816903` - Gyni™ Study With Leumit Health Services	N/A
Completed	`NCT05670535` - Sjögren and Gynecologic Considerations
Not yet recruiting	`NCT06438575` - Point of Care Diagnosis of Vaginal Infections	N/A
Enrolling by invitation	`NCT04984460` - Morphological Detection of Liquid-based Thin-layer Film-making Fungi for Fungal Vaginitis in Multiple Hospitals
Completed	`NCT03151928` - Diagnostic Accuracy By Providers Study

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

Open Study of the Efficacy of the Local Treatment With Polygynax of Bacterial and/or Mycotic Vaginitis

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms